Selection, technique, and follow-up: keys to success in EVAR
Short-term survival benefi ts of endovascular aneurysm repair (EVAR) versus open repair of elective abdominal aortic aneurysms have been shown in randomised trials, but this early survival benefi t is lost within a few years.
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The long-term survival benefi t of EVAR remains unclear. 4 The randomised controlled EVAR trial 1 was initiated in 1999, and the EVAR trial participants and authors are to be congratulated for their persistence to obtain these long-term data in this aneurysm population suitable for both open repair and EVAR.
1 In Rajesh Patel and colleagues' EVAR trial 1 5 reported in The Lancet, over a mean of 12·7 years' follow-up (max 15·8 years), they show no signifi cant diff erence between the randomly assigned groups in total mortality (9·3 deaths per 100 person-years in the EVAR group vs 8·9 deaths per 100 person-years in the open-repair group) or aneurysm-related mortality (1·1 deaths per 100 person-years in the EVAR group vs 0·9 deaths per 100 person-years in the open-repair group). An early and signifi cant survival benefi t was noted in the EVAR group at 6 months after randomisation (adjusted hazard ratios 0·61, 95% CI 0·37-1·02 for total mortality; and 0·47, 0·23-0·93, p=0·031 for aneurysm-related mortality), and only after 8 years did open repair have a signifi cantly lower mortality (1·25, 1·00-1·56, p=0·05 for total mortality; and 5·82, 1·64-20·65, p=0·006 for aneurysm-related mortality). The increased aneurysmrelated mortality beyond 8 years was mainly attributable to secondary aneurysm sac rupture post-EVAR. Overall, aneurysm re-intervention rates were higher in the EVAR than in the open-repair group (4·1 and 1·7 per 100 person-years; p<0·0001) with most re-interventions taking place within 4 years of the initial treatment. 5 In this trial, patients were treated more than 12 years ago and, fortunately, medical and endovascular management have since progressed. Case selection, device choice, 6 and planning with technical skills by use of simulation, 7 imaging modalities with decreased radiation, best practices in medical treatment, and surveillance programmes in centralised aortic units have all improved the overall management of aortic aneurysmal disease. 8 Although the EVAR trial 1 will always be a landmark trial, the long-term fi ndings with only 57% of patients being alive at the end of follow-up should be interpreted with caution because of the following limitations.
The data collection from 10-15 years risks bias since it was done both retrospectively and prospectively, and relies on data from NHS records for procedures at the time of patient discharge (Hospital Episode
In 1999, the mean age at randomisation for the EVAR trial 1 was 74 years, indicating that patients were a high-risk group for malignancy based on age rather than radiation exposure. The diff erence in total malignancy deaths at 15 years is small (126 in the EVAR group vs 123 in the open-repair group) and in fact more malignancy deaths were noted in the open-repair group at time intervals 6 months to 4 years and at 4-8 years. Appropriate investigation and robust data are needed and any insinuation that EVAR predisposes to or increases the risk of cancer might be dangerously misleading.
The long-term surveillance after aneurysm repair in the UK trial, a country known for its evidence-based medicine, was astonishingly low despite reports warning the endovascular community about the importance of lifelong follow-up. 9 Unfortunately, imaging data have not yet been included to explain why aneurysms excluded with second and third generation devices still rupture during long-term follow-up. Was this aneurysm growth or rupture caused by true device failures 10 (eg, fractures, migration, endoleak type I or III), or was the initial stent graft not deployed within 3 mm of the lowest renal artery? Was surveillance continued for long enough (median CT surveillance six scans 
and were serious and life-threatening complications managed appropriately by secondary interventions (such as by relining, coiling, proximal fenestrated cuff ) to save the patient's life? 10 Local investigators in this trial by Patel and colleagues 5 were at liberty to treat patients to their best knowledge, but some complications that are now known to cause aneurysm rupture were not treated.
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EVAR has gained enormous popularity worldwide with a lower initial operative mortality than open repair. Secondary ruptures after EVAR account for the long-term increase in aneurysm-related mortality. These fi ndings, confi rmed by 15 years of follow-up data from the EVAR 1 trial, 5 should alert physicians managing abdominal aortic aneurysms and might have implications for case selection, patients' treatment choices, and continuous surveillance after EVAR. These results also show that long-term follow-up of surgical innovations is crucial. 
